Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.47 USD | +6.01% | +7.86% | -17.39% |
Financials (USD)
Sales 2024 * | 323M | Sales 2025 * | 420M | Capitalization | 468M |
---|---|---|---|---|---|
Net income 2024 * | -9M | Net income 2025 * | 49M | EV / Sales 2024 * | 0.76 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.3 x |
P/E ratio 2024 * |
-43.9
x | P/E ratio 2025 * |
12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +6.01% | ||
1 week | +7.86% | ||
Current month | +14.35% | ||
1 month | +16.51% | ||
3 months | +0.41% | ||
6 months | +64.67% | ||
Current year | -17.39% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 234 M€ | +11.44% | - | |
0.00% | 2 M€ | -.--% | ||
0.00% | 1,487 M€ | +8.50% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 2.47 | +6.01% | 10,540,099 |
24-06-05 | 2.33 | +3.56% | 4,149,875 |
24-06-04 | 2.25 | +0.45% | 6,518,257 |
24-06-03 | 2.24 | +3.70% | 6,865,518 |
24-05-31 | 2.16 | -5.68% | 5,947,710 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.39% | 441M | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+8.78% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B |
- Stock Market
- Equities
- ESPR Stock